Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01547832 · ClinicalTrials.gov registry record
Mutations Associated With Parkinson s Disease
A clinical trial, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Terminated
- Registry status
- 42
- Enrollment target
NCT01547832: Clinical Trial study, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
NCT01547832 is a clinical trial that was terminated before completion, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 42 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01547832 was terminated before completion, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- TERMINATED
- Registry status
- 42 participants
- Enrollment target
Study Summary
Background: \- Early-onset Parkinson's disease (EOPD) is more likely to be caused by gene mutations than Parkinson's disease that develops in older people. Studying these mutations may help find therapies for EOPD. Researchers want to study mutations on a gene called PARK2. These mutations prevent fat uptake into cells and may interfere with normal brain function. Researchers want to study fat and cholesterol in the body to look at the effects of these mutations on the body and brain. Objectives: \- To study connections between genetic mutations and EOPD. Eligibility: * Individuals between 18 and 80 years of age with EOPD. * Individuals between 18 and 80 years of age with no family history of Parkinson s disease. Design: * Participants will be screened with a physical exam and medical history. Blood and urine samples will also be collected. * Participants will have some or all of the following tests: * Blood samples and tissue (skin and fat) biopsies * Cell line development from these tissue samples to study the function of PARK2 * DEXA scan to measure body fat context using low dose x-rays * Glucose and insulin tolerance testing to measure blood sugar levels. * Treatment will not be provided as part of this protocol.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2012-02-27 |
| Est. Completion | 2018-08-27 |
Why NCT01547832 stopped before completion
NCT01547832 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 42 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01547832 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01547832 about?
NCT01547832 is a clinical study titled "Mutations Associated With Parkinson s Disease". Background: \- Early-onset Parkinson's disease (EOPD) is more likely to be caused by gene mutations than Parkinson's disease that develops in older people. Studying these mutations may help find therapies for EOPD. Researchers want to study mutations on a gene called PARK2. These mutations prevent ...
What is the current status of trial NCT01547832?
This trial is currently terminated. The enrollment target is 42 participants. The study started on 2012-02-27. Estimated completion is 2018-08-27.
Who is sponsoring clinical trial NCT01547832?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI